Abstract
In recent years, molecular research has brought to light a series of mechanisms involved in the regulation of gene function without altering the DNA sequence. These mechanisms are described with the term “epigenetics” and include modifications in the structure of the human genome, leading to heritable and potentially reversible changes in gene expression. There is now increasing evidence suggesting that several characteristic features of chronic kidney disease such as hyperhomocysteinemia, subclinical inflammation, increased oxidative stress and others may affect the human epigenome. In addition, animal studies have suggested a possible link between nutrition and environmental exposure during the periconceptional period and epigenetic changes in the expression of major genes implicated in kidney organogenesis; these changes result in a diminished number of nephrons in the developing kidney, which predisposes to an increased risk for hypertension and chronic kidney disease in future life. The understanding of the role of epigenetic phenomena in the pathogenesis of chronic kidney disease opens new avenues for future therapeutic strategies, through the development of pharmaceutical agents that target directly with the changes in the human epigenome. Such epigenetic drugs are already in clinical use for the treatment of cancer as well as under investigation for the use in other diseases. This review will summarize the existing data on the link between epigenetic mechanisms and chronic uremic milieu, as well as the promising results of ongoing research in the field of epigenetic drugs that could represent additional options in our therapeutic armamentarium for patients with chronic kidney disease.
Keywords: Chronic kidney disease, diabetic nephropathy, epigenetics, kidney organogenesis, transplantation, genome, hyperhomocysteinemia, subclinical, environmental exposure
Current Medicinal Chemistry
Title: Epigenetic Mechanisms and Kidney Diseases
Volume: 18 Issue: 12
Author(s): V. Liakopoulos, P. I. Georgianos, T. Eleftheriadis and P. A. Sarafidis
Affiliation:
Keywords: Chronic kidney disease, diabetic nephropathy, epigenetics, kidney organogenesis, transplantation, genome, hyperhomocysteinemia, subclinical, environmental exposure
Abstract: In recent years, molecular research has brought to light a series of mechanisms involved in the regulation of gene function without altering the DNA sequence. These mechanisms are described with the term “epigenetics” and include modifications in the structure of the human genome, leading to heritable and potentially reversible changes in gene expression. There is now increasing evidence suggesting that several characteristic features of chronic kidney disease such as hyperhomocysteinemia, subclinical inflammation, increased oxidative stress and others may affect the human epigenome. In addition, animal studies have suggested a possible link between nutrition and environmental exposure during the periconceptional period and epigenetic changes in the expression of major genes implicated in kidney organogenesis; these changes result in a diminished number of nephrons in the developing kidney, which predisposes to an increased risk for hypertension and chronic kidney disease in future life. The understanding of the role of epigenetic phenomena in the pathogenesis of chronic kidney disease opens new avenues for future therapeutic strategies, through the development of pharmaceutical agents that target directly with the changes in the human epigenome. Such epigenetic drugs are already in clinical use for the treatment of cancer as well as under investigation for the use in other diseases. This review will summarize the existing data on the link between epigenetic mechanisms and chronic uremic milieu, as well as the promising results of ongoing research in the field of epigenetic drugs that could represent additional options in our therapeutic armamentarium for patients with chronic kidney disease.
Export Options
About this article
Cite this article as:
Liakopoulos V., I. Georgianos P., Eleftheriadis T. and A. Sarafidis P., Epigenetic Mechanisms and Kidney Diseases, Current Medicinal Chemistry 2011; 18 (12) . https://dx.doi.org/10.2174/092986711795496827
DOI https://dx.doi.org/10.2174/092986711795496827 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Quercetin against Mycotoxin Induced Cytotoxicity: A Mini- Review
Current Nutrition & Food Science New Challenges for ACE-Inhibitors in Vascular Diseases
Drug Design Reviews - Online (Discontinued) Effect of Simultaneous Snail Slime-aided Degradation and Yeast Fermentation on Terpenoid Composition of Plantain Pseudostem Waste
Current Pharmaceutical Biotechnology Redox Mechanisms of Vascular Cell Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Review of Evidence that Epidemics of Type 1 Diabetes and Type 2 Diabetes/ Metabolic Syndrome are Polar Opposite Responses to Iatrogenic Inflammation
Current Diabetes Reviews Molecular Foundations for Personalized Therapy in Prostate Cancer
Current Drug Targets Determinants of Perceived Severity of Hypertension and Drug-Compliance in Hypertensive Patients
Cardiovascular & Hematological Disorders-Drug Targets B-Type Natriuretic Peptide for Diagnosis and Therapy
Recent Patents on Cardiovascular Drug Discovery Chronopharmaceutical Delivery of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets Oxidative Stress and Endothelial Dysfunction: Say NO to Cigarette Smoking!
Current Pharmaceutical Design ALDH2---The Genetic Polymorphism and Enzymatic Activity Regulation: Their Epidemiologic and Clinical Implications
Current Drug Targets Matrix Metallopropteinases in Heart Failure
Current Topics in Medicinal Chemistry Erythrocyte Amyloid Beta Peptide Isoform Distributions in Alzheimer and Mild Cognitive Impairment
Current Alzheimer Research Meet the Editorial Board:
Medicinal Chemistry Etiopathogenesis and Treatment of Parkinsons Disease
Current Topics in Medicinal Chemistry Differential Impacts of Antihypertensive Drugs on Central Blood Pressure and Their Clinical Significance
Current Hypertension Reviews Editorial [Hot Topic: Cardiovascular Risk and Inflammation: Pathophysiological Mechanisms, Drug Design, and Targets Executive (Guest Editor: Armen Yuri Gasparyan)]
Current Pharmaceutical Design Insulin Resistance, Obesity and the Metabolic Syndrome. Is there a Therapeutic Role for Endothelin-1 Antagonists?
Current Vascular Pharmacology Therapeutic Potential for Thyroid Hormone Receptor-β Selective Agonists for Treating Obesity, Hyperlipidemia and Diabetes
Current Vascular Pharmacology